Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?

References

• AlmansaCGomezLAde ArribaAFDiphenypropionic acids as new AT-1 selective angiotensin II antagonistsJ Med Chem19963921972068667363
   PubMed Web of Science ®Google Scholar
• BangaloreKamalakkannanPanjrathFixed-dose combination improves medication compliance: a meta analysis [abstract]J Clin Hyper20068A71
   Google Scholar
• BarnettAHBainSCBouterPAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med200435119526115516696
   PubMed Web of Science ®Google Scholar
• BattershillAJScottLJTelmisartan: a review of its use in the management of hypertensionDrugs200666518316398568
   PubMed Web of Science ®Google Scholar
• BeermannBGroschinsky-GrindMPharmacokinetics of hydrochlorothiazide in manEur J Clin Pharmacol197712297303590315
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHAHoCIIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activityHypertension200443993100215007034
   PubMed Web of Science ®Google Scholar
• BloomBSContinuation of initial antihypertensive medication after 1 year of therapyClin Ther199820671819737827
   PubMed Web of Science ®Google Scholar
• BogerRHSchwedhelmEMaasRADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI studyVasc Med200510Suppl 1S9710216444875
   PubMedGoogle Scholar
• BöhmMLeeMKreutzRAngiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin system gene expression and cardiovascular functionsJ Hypertens19951389198557967
   PubMed Web of Science ®Google Scholar
• BöhmMLippoldtAWienenWreduction of cardiac hypertrophy in TGR(mREN2)97 by angiotensin II receptor blockadeMol Cell Biochem19961634217218974060
   PubMedGoogle Scholar
• BourgaultCSenecalMBrissonMPersistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based studyJ Hum Hypertens2005196071315920457
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEDe ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyNew Engl J Med2001345861911565518
   PubMed Web of Science ®Google Scholar
• BrondoloERosenRCKostisJBRelationship of physical symptoms and mood to perceived and actual blood pressure in hypertensive men: a repeated-measures designPsychosom Med1999613111810367611
   PubMed Web of Science ®Google Scholar
• BrunnerHRWaeberBNussbergerJResponsiveness of renin secretion: The key to understanding the efficacy of inhibition of the renin-angiotensin systemKidney Int198834805
   Web of Science ®Google Scholar
• ChenLingCuddyPharmacological characterization of two new angiotensin II receptor antagonists, WAY-126277 and WAY-126756 [abstract]Circ Res199388I2330 I-433, 2330
   Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034212065214656957
   PubMed Web of Science ®Google Scholar
• CifkovaRErdineSFagardRPractice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelinesJ Hypertens20032117798614508180
   PubMedGoogle Scholar
• ConlinPRGerthWCFoxJFour-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classesClin Ther2001231999201011813934
   PubMed Web of Science ®Google Scholar
• de GasparoMUngerTSchölkensBAAT-1 Receptor Antagonists: PharmacologyAngiotensin - Vol II - Part 5. Inhibition of the Renin-Angiotensin System. Series: Handbook of Experimental Pharmacology (Vol 163)2004Springer Verlag41752
   Google Scholar
• DerosaGCiceroAFBertoneGComparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind studyClin Ther2004a2612283615476904
   PubMed Web of Science ®Google Scholar
• DerosaGRagonesiPDMugelliniAEffects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month studyHypertens Res2004b274576415302981
   PubMed Web of Science ®Google Scholar
• DeziiCMA retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertensionManag Care200092611729417
   PubMedGoogle Scholar
• DiezJGonzalezALopezBRavassaSFortunoMAEffects of antihypertensive agents on the left ventricle: clinical implicationsAm J Cardiovasc Drugs200112637914728026
   PubMedGoogle Scholar
• ElliotWJDifferential effects of antihypertensive drugs on new-onset diabetes?Curr Hypertens Rep200572495616061042
   PubMed Web of Science ®Google Scholar
• EpsteinMBakrisGNewer approaches to antihypertensive therapyArch Intern Med19961561969788823150
   PubMed Web of Science ®Google Scholar
• FalconnetCBochudMBovetPGender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of Africa descentJ Hypertens20042212132015167457
   PubMedGoogle Scholar
• FentonCKeatingGMScottLJTelmisartan/hydrochlorothiazide. In the treatment of essential hypertensionDrugs20036320132612962518
   PubMed Web of Science ®Google Scholar
• FreytagFHolwerdaNJKarlbergBELong-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safetyBlood Press2002111738112126264
   PubMed Web of Science ®Google Scholar
• FreytagFSchellingAMeinickeTComparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter studyClin Ther2001231082311219471
   PubMed Web of Science ®Google Scholar
• GalzeranoDTammaroPCercielloAFreehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre studyJ Hum Hypertens20041853914688811
   PubMed Web of Science ®Google Scholar
• GohlkePWeissSJansenAAT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin ii in conscious ratsJ Pharmacol Exp Ther2001298627011408526
   PubMed Web of Science ®Google Scholar
• GrossmanEMesserliFHLong term safety of antihypertensive therapyProg Cardiovasc Dis200649162516867847
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trialThe Lancet1998351175562
   PubMed Web of Science ®Google Scholar
• IsrailiZHHallWDCough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiologyAnn Intern Med1992117234421616218
   PubMed Web of Science ®Google Scholar
• KarlbergBELinsLEHermanssonKEfficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study GroupJ Hypertens19991729330210067800
   PubMed Web of Science ®Google Scholar
• KjellgrenKIAhlnerJDahlofBPatients’ and physicians’ assessment of risks associated with hypertension and benefits from treatmentJ Cardiovasc Risk19985161610201552
   PubMedGoogle Scholar
• KurtzTWTreating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator2Acta Diabetol200542Suppl 1S91615868121
   PubMedGoogle Scholar
• LacourciéreYA new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazideJ Int Med Res2002303667912235918
   PubMed Web of Science ®Google Scholar
• LacourciéreYGil-ExtremeraBMuellerOEfficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertensionInt J Clin Pract20031756975
   Google Scholar
• LacourciéreYMartinKComparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertensionAm J Ther200291111711897925
   PubMedGoogle Scholar
• LacourciereYNeutelJMSchumacherHComparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials1Clin Ther200527179580516368450
   PubMed Web of Science ®Google Scholar
• LacourciéreYTytusRO’KeefeDEfficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapyJ Hum Hypertens2001157637011687919
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013458516011565517
   PubMed Web of Science ®Google Scholar
• MaillardMBurnierMTelmisartan/hydrochlorothiazide: a new fixed dose combinationExpert Rev Cardiovasc Ther200533758615889965
   PubMedGoogle Scholar
• MaillardCentenoWienenMolecular basis for the insurmountable AT-1 receptor antagonism of telmisartan [abstract]Am J Hypertens20011412A
   Google Scholar
• MaillardMPerregauxCCentenoCIn vitro and in vivo characterization of telmisartan: an insurmountable angiotensin II receptor antagonistJ Pharmacol Exp Ther200230210899512183667
   PubMed Web of Science ®Google Scholar
• MakinoHHanedaMBabazonoTThe telmisartan renoprotective study from incipient nephropathy to overt nephropathy—rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) StudyJ Int Med Res2005336778616372586
   PubMed Web of Science ®Google Scholar
• ManciaTolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo [abstract]J Hypertens Suppl200220S377
   Google Scholar
• MarshallTGLeeREMarshallFECommon angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2bTheor Biol Med Model20063116403216
   PubMed Web of Science ®Google Scholar
• MattioliAVZennaroMBonattiSRegression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartanInt J Cardiol200497383815561322
   PubMed Web of Science ®Google Scholar
• McGillJBReillyPACombination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertensionClin Cardiol2001a24667211195609
   PubMed Web of Science ®Google Scholar
• McGillJBReillyPATelmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trialClin Ther2001b238335011440284
   PubMed Web of Science ®Google Scholar
• MeredithPAAngiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effectAm J Cardiovasc Drugs200551718315901205
   PubMedGoogle Scholar
• MichelMCBohnerHKosterJSafety of telmisartan in patients with arterial hypertension: an open-label observational studyDrug Saf2004273354415061687
   PubMed Web of Science ®Google Scholar
• MiuraYYamamotoNTsunekawaSReplacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequencesDiabetes Care200528757815735228
   PubMed Web of Science ®Google Scholar
• NeldamSEdwardsCTelmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring studyAm J Geriatr Cardiol2006151516016687967
   PubMed Web of Science ®Google Scholar
• NeutelJMFrishmanWHOparilSComparison of telmisartan with lisinopril in patients with mild-to-moderate hypertensionAm J Ther1999a6161610423659
   PubMedGoogle Scholar
• NeutelJMKleinCMeinickeTWLong-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medicationsBlood Press200211302912458653
   PubMed Web of Science ®Google Scholar
• NeutelJMKollochREPlouinPFTelmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomized ABPM studyJ Hum Hypertens2003175697512874615
   PubMed Web of Science ®Google Scholar
• NeutelJMSmithDHGReillyPAThe efficacy and safety of telmisartan compared to enalapril in patients with severe hypertensionInt J Clin Pract1999b53175810665127
   PubMed Web of Science ®Google Scholar
• NeutelJMSmithDHGTelmisartan US Study GroupDose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild-to-moderate hypertensionAdv Therapy19981520617
   Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med2001345870811565519
   PubMed Web of Science ®Google Scholar
• PickkersPGarchaRSSchachterMInhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazideHypertension1999331043104810205245
   PubMed Web of Science ®Google Scholar
• PittasAGGreenbergASThiazolidinediones in the treatment of type 2 diabetesExpert Opin Pharmacother200235294011996632
   PubMedGoogle Scholar
• ResnickLMWhy we can’t translate clinical trials into clinical practice in hypertensionAm J Hypertens200316421512745206
   PubMed Web of Science ®Google Scholar
• ReyesAJCardiovascular drugs and serum uric acidCardiovasc Drugs Ther20031739741415107595
   PubMed Web of Science ®Google Scholar
• RiesUMihmGNarrB6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationshipsJ Med Chem1993364040518258826
   PubMed Web of Science ®Google Scholar
• SchierokHJPairetMHauelNEffects of telmisartan on renal excretory function in conscious dogsJ Intern Med2001291319
   Google Scholar
• SchmiederRETelmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertensionExpert Opin Pharmacother2004523031015500377
   PubMed Web of Science ®Google Scholar
• SchuppMClemenzMGinesteRMolecular characterization of new selective peroxisome proliferator-activated receptor {gamma} modulators with angiotensin receptor blocking activityDiabetes2005543442345216306360
   PubMed Web of Science ®Google Scholar
• SchuppMJankeJClasenRAngiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activityCirculation20041092054715117841
   PubMed Web of Science ®Google Scholar
• SengulAMAltuntasYKurkluABeneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertensionDiabetes Res Clin Pract2006712101916112244
   PubMed Web of Science ®Google Scholar
• SharpeMJarvisBGoaKLTelmisartan: A review of its use in hypertensionDrugs20016115012911558835
   PubMed Web of Science ®Google Scholar
• SicaDAFixed-dose combination antihypertensive drugs. Do they have a role in rational therapyDrugs19944816247525192
   PubMed Web of Science ®Google Scholar
• SiscovickDSRaghunathanTEPsatyBMDiuretic therapy for hypertension and the risk of primary cardiac arrest 1N Engl J Med1994330185278196728
   PubMed Web of Science ®Google Scholar
• StangierJSchmidJTurkDAbsorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteersJ Clin Pharmacol20004013122211185629
   PubMed Web of Science ®Google Scholar
• StangierJSuCAPvan HeiningenPNMInhibitory effect of telmisartan on the blood pressure response to angiotensin II challengeJ Cardiovasc Pharmacol2001386728511602814
   PubMed Web of Science ®Google Scholar
• TaylorAAShoheiberOAdherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapyCongest Heart Fail200393243214688505
   PubMedGoogle Scholar
• TeoKYusufSSleightPRationale, design, and baseline characteristics of two large, simple, randomized trials evaluating telmisartan, ramipiril and their combination in high-risk patients: the ONgoing Telmisartan Alone and combination with Ramipiril Global Endpoint Trial / Telmisartan Randomized Assessment study in ACE intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trialsAm J Heart20041485261
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALHAT Collaborative Research GroupMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)JAMA200228829819712479763
   PubMed Web of Science ®Google Scholar
• UngerTKaschinaEDrug interactions with angiotensin receptor blockers: a comparison with other antihypertensivesDrug Safety2003267072012862505
   PubMed Web of Science ®Google Scholar
• Van BrummelenPMan in’t VeldAJSchalekampMAHaemodynamic changes during long term thiazide treatment of essential hypertension in responders and non-respondersClin Pharmacol Ther198027328366987024
   PubMed Web of Science ®Google Scholar
• van Heiningenvan Lierde BruinSingle dose study on the pharmacodynamics and pharmacokinetics of the angiotensin II receptor antagonist BIBR0277SE [abstract]Pharm World Sci1994164
   Google Scholar
• Van MeelJCARedemannNHaighRMhypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic ratsArzneim-Forsh /Drug Res19964675599125273
   PubMed Web of Science ®Google Scholar
• VitaleCMercuroGCastiglioniCMetabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromeCardiovasc Diabetol20054615892894
   PubMed Web of Science ®Google Scholar
• VogtLNavisGKosterJThe angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trialJ Hypertens20052320556116208149
   PubMed Web of Science ®Google Scholar
• WaeberBCombination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretic in hypertensionExpert Rev Cardiovasc Ther20031435015030296
   PubMedGoogle Scholar
• WeberMThe telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programmeJ Hypertens200321S37S46
   PubMed Web of Science ®Google Scholar
• WhiteWBComparative effects of telmisartan in the treatment of hypertensionJ Clin Hypertens (Greenwich)2002420512147925
   PubMedGoogle Scholar
• [WHO] World Health OrganizationCardiovascular disease: prevention and control. [online]2003 Accessed 18 June 2006. URL: http://www.who.int/dietphysicalactivity/publications/facts/cvd/en
   Google Scholar
• WienenWEntzerothMEffects on binding chracteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR-277 in the ratJ Hypertens199412119288021462
   PubMed Web of Science ®Google Scholar
• WienenWEntzerothMVan MeelJCAA review on telmisartan: a novel, long-acting angiotensin II receptor antagonistCardiovasc Drug Rev20001812756
   Google Scholar
• WienenWHauelNVan MeelJCAPharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277Br J Pharmacol1993110245528220885
   PubMed Web of Science ®Google Scholar
• WienenWRichardSChamperouxPComparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic ratsJRAAS20012313611881063
   PubMedGoogle Scholar
• WienenWSchierokHJEffects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in sponeneously hypertensive ratsJ Renin Angiotensin Aldosterone Syst20012123811881111
   PubMed Web of Science ®Google Scholar
• WillichSNLevyDRoccoMBCircadian variation in the incidence of sudden cardiac death in the Framingham Heart Study populationAm J Cardiol19876080163661393
   PubMed Web of Science ®Google Scholar
• WogenJKreilickCALivorneseRCPatient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care settingJ Manag Care Pharm20039424914613440
   PubMedGoogle Scholar
• WuerznerKHasslerCBurnierMDifficult blood pressure control: watch out for non-compliance!Nephrol Dial Transplant20031819697313679466
   PubMed Web of Science ®Google Scholar
• YoungCLDiasVCStangierJMultiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjectsJ Clin Pharmacol20004013233011185630
   PubMed Web of Science ®Google Scholar
• ZanchiAChioléroAMaillardMEffects of the Peroxisomal Proliferator-Activated Receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy menJ Clin Endocr Metab2004891140515001599
   PubMed Web of Science ®Google Scholar